Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 10 | 2024 | 261 | 3.290 |
Why?
|
| Critical Illness | 8 | 2023 | 120 | 3.080 |
Why?
|
| Sepsis | 7 | 2020 | 115 | 2.690 |
Why?
|
| Critical Care | 7 | 2024 | 120 | 2.650 |
Why?
|
| Physicians | 3 | 2021 | 123 | 1.810 |
Why?
|
| Family | 4 | 2024 | 95 | 1.630 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 46 | 1.070 |
Why?
|
| Staphylococcal Infections | 5 | 2020 | 163 | 1.070 |
Why?
|
| Hospital Mortality | 3 | 2020 | 141 | 1.060 |
Why?
|
| Anxiety | 3 | 2023 | 153 | 1.010 |
Why?
|
| Neoplasms | 2 | 2020 | 241 | 0.940 |
Why?
|
| Depression | 3 | 2023 | 439 | 0.840 |
Why?
|
| Communication | 2 | 2023 | 92 | 0.790 |
Why?
|
| Stress, Psychological | 2 | 2021 | 228 | 0.760 |
Why?
|
| Humans | 24 | 2024 | 26976 | 0.760 |
Why?
|
| Palliative Medicine | 1 | 2021 | 8 | 0.730 |
Why?
|
| Bacteremia | 4 | 2020 | 99 | 0.730 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 73 | 0.720 |
Why?
|
| Adult | 13 | 2022 | 7877 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 228 | 0.650 |
Why?
|
| Patient Advocacy | 1 | 2019 | 13 | 0.640 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 19 | 0.640 |
Why?
|
| HIV Infections | 2 | 2016 | 466 | 0.610 |
Why?
|
| Tracheostomy | 1 | 2018 | 24 | 0.600 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.600 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 8 | 0.600 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 35 | 0.580 |
Why?
|
| Patient Care Team | 1 | 2019 | 109 | 0.580 |
Why?
|
| Chronic Disease | 1 | 2019 | 417 | 0.560 |
Why?
|
| Middle Aged | 13 | 2021 | 9017 | 0.550 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 5 | 0.520 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 9 | 0.500 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 109 | 0.480 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 53 | 0.470 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 121 | 0.460 |
Why?
|
| Aged | 11 | 2021 | 9068 | 0.460 |
Why?
|
| Decision Making | 3 | 2021 | 217 | 0.450 |
Why?
|
| Immune System Diseases | 1 | 2014 | 1 | 0.440 |
Why?
|
| Male | 13 | 2021 | 14756 | 0.440 |
Why?
|
| Female | 13 | 2021 | 15196 | 0.430 |
Why?
|
| Algorithms | 1 | 2016 | 350 | 0.420 |
Why?
|
| Pandemics | 2 | 2021 | 237 | 0.320 |
Why?
|
| Cytokines | 3 | 2020 | 235 | 0.310 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3543 | 0.300 |
Why?
|
| Cross Infection | 1 | 2011 | 305 | 0.300 |
Why?
|
| Hospitalization | 3 | 2021 | 310 | 0.290 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1135 | 0.250 |
Why?
|
| Prognosis | 2 | 2020 | 804 | 0.250 |
Why?
|
| Chicago | 2 | 2019 | 936 | 0.240 |
Why?
|
| Influenza, Human | 2 | 2016 | 47 | 0.240 |
Why?
|
| Length of Stay | 2 | 2018 | 320 | 0.240 |
Why?
|
| Age Factors | 2 | 2018 | 773 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 349 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 891 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 9 | 0.210 |
Why?
|
| Consensus | 1 | 2023 | 92 | 0.200 |
Why?
|
| Th2 Cells | 2 | 2019 | 17 | 0.180 |
Why?
|
| Morals | 1 | 2021 | 14 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2021 | 1782 | 0.180 |
Why?
|
| Th17 Cells | 2 | 2019 | 33 | 0.180 |
Why?
|
| Sleep | 1 | 2024 | 324 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 4833 | 0.170 |
Why?
|
| Body Temperature | 1 | 2020 | 40 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 14 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 96 | 0.170 |
Why?
|
| Palliative Care | 1 | 2021 | 109 | 0.170 |
Why?
|
| Uncertainty | 1 | 2020 | 9 | 0.170 |
Why?
|
| United States | 3 | 2021 | 2029 | 0.170 |
Why?
|
| Logistic Models | 2 | 2018 | 394 | 0.160 |
Why?
|
| ROC Curve | 2 | 2018 | 140 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 19 | 0.160 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 2 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 42 | 0.150 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 5 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2019 | 65 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 2313 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 23 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 17 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 28 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 119 | 0.140 |
Why?
|
| Flow Cytometry | 1 | 2018 | 110 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 35 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 274 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 299 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 411 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 462 | 0.140 |
Why?
|
| Quality of Life | 1 | 2021 | 622 | 0.130 |
Why?
|
| APACHE | 1 | 2016 | 27 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2018 | 588 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2016 | 11 | 0.130 |
Why?
|
| Coinfection | 1 | 2016 | 21 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 13 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 460 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2016 | 54 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2016 | 32 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 19 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1431 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 352 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antioxidant Response Elements | 1 | 2013 | 1 | 0.110 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 23 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2013 | 93 | 0.100 |
Why?
|
| Georgia | 1 | 2011 | 11 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 60 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 176 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 69 | 0.090 |
Why?
|
| HIV-1 | 1 | 2013 | 226 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 506 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2016 | 548 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2016 | 609 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3526 | 0.050 |
Why?
|
| Child | 2 | 2016 | 1240 | 0.050 |
Why?
|
| Fever | 1 | 2020 | 34 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2020 | 59 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 2147 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2016 | 0.040 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 27 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 26 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 3602 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2019 | 46 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 101 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 310 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 168 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 443 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 348 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 483 | 0.030 |
Why?
|
| Asthma | 1 | 2019 | 148 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 590 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 261 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 13 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 87 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 70 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1416 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 168 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 486 | 0.030 |
Why?
|
| Quinones | 1 | 2013 | 1 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2013 | 5 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2013 | 5 | 0.030 |
Why?
|
| Thiocyanates | 1 | 2013 | 4 | 0.030 |
Why?
|
| Occludin | 1 | 2013 | 8 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Claudins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2013 | 13 | 0.030 |
Why?
|
| Glutathione | 1 | 2013 | 22 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 762 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 37 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1900 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 100 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2013 | 309 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 523 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 637 | 0.020 |
Why?
|